Inspira Health Network Expands Utilization of the DoseMeRx Platform

DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced Inspira has expanded the implementation of the dosing platform to serve the newly acquired Mannington site. Inspira has used DoseMeRx since 2020 and integrates with EHR software for faster, efficient access to patient profiles for overall better quality of care.

Kindeva Appoints Daniel J. Speciale as the New Chief Financial Officer (CFO)

Sphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selection

First multiplexed solution introduced with the next-generation Cyto-Mine Chroma platform for more efficient biotherapeutic development Utilizes advanced picodroplet microfluidics technology to integrate analysis of antibody productivity and cell viability of monoclonal antibody producing cells

Andaman7 Seeks $5m to Continue Investment in Pioneering Technology

Andaman7, the platform transforming healthcare communications and bridging the gap between patients and researchers, is seeking investment to reach the next milestones in its ground-breaking journey.

Inizio Medical Launches iON.AI to Transform Medical Affairs Capabilities

Mayo Clinic Laboratories and Amprion announce collaboration to advance neurodegenerative disease diagnostics

Mayo Clinic Laboratories and Amprion announced a strategic collaboration to expand access to Amprion’s SAAmplify™–αSYN (CSF) test across the U.S.

PwC certifies KELES as first VC-firm to achieve SFDR Article 9 for digital health investment

DNAnexus Announces Collaboration with AlidaBio to Enhance RNA Modification and Expression Analysis

DNAnexus announces collaboration with AlidaBio to advance epitranscriptomics research and discovery.

Novartis Strengthens Cardiovascular Portfolio with $3.08 Billion Anthos Therapeutics Acquisition

Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.

Femasys Secures European Approval for FemBloc Delivery System, Paving the Way for the First Non-Surgical Permanent Birth Control

European women will soon be able to receive permanent birth control through a non-surgical approach. FemBloc, developed by Femasys, a leading biomedical innovator addressing significant unmet needs in women's health worldwide, announces Conformité Européene (CE) mark certification under the European Union Medical Device Regulation (EU MDR) as the first regulatory approval in the world for the FemBloc® delivery system for non-surgical female permanent birth control.

Coronado Research Announce the Appointment of Gary Lyons as EVP Medical Affairs

Coronado Research has appointed Gary Lyons as EVP Medical Affairs. Gary is a seasoned senior Medical Affairs leader with extensive strategic and operational implementation experience across the industry and product lifecycle.

InSysBio announces its collaboration with discoveric bio alpha

The project aims at mechanistic modeling of antibodies to predict pharmacokinetics and target occupancy in cerebrospinal fluid.

CariGenetics launches Caribbean Genome Programme with Oxford Nanopore to drive regional genomic research

CariGenetics and Oxford Nanopore Technologies have launched the Caribbean Genome Programme, the first large-scale genomic sequencing initiative in the region. This pioneering effort is set to address unmet need in advancing regional genetic research in the Caribbean, providing real-time, high throughput sequencing to address critical health disparities, starting with men’s health.

InformedDNA Acquires Coriell Life Sciences, Expanding Precision Health Capabilities

InformedDNA has acquired Coriell Life Sciences, a provider of pharmacogenomic services and clinical decision support. The combination significantly expands patient, provider and payor access to a broader range of genetic insights and enables more personalized, data-driven treatment and medication decisions for better outcomes and reduced healthcare costs.

Proscia Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of Precision Medicine

Funding led by global software investor Insight Partners comes as the surge in cancer cases compounds the impact of the shrinking pathologist workforce.

START Further Expands Its Global Oncology Site Network with the Addition of Carolina Urologic Research Center

START's site network solidifies its global leadership in urological cancer trials.

Sirio Launches Global Research Institute for Longevity Studies [SIA]

Clearwater Joins CancerX to Help Drive Strong Cybersecurity and Data Privacy Practices in the Fight Against Cancer

Zymo Research Responds to Recent Court Ruling in Litigation with QIAGEN GmbH

This press release highlights the recent ruling by the United States District Court for the Central District of California, which denied QIAGEN’s Partial Motion to Dismiss and, in the alternative, to stay counterclaims brought by Zymo Research, including claims of patent unenforceability and antitrust violations.

Sapio Sciences Makes AI-Native Drug Discovery Seamless with NVIDIA BioNeMo

Sapio Sciences today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into Sapio ELN (Electronic Lab Notebook), helping to streamline workflows and improve decision-making in drug discovery.